15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for GTBP yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $5.95 current
Highest Target—
Average Target—
Lowest Target—
GTBP analyst recommendation trends
86420
Sep
Oct
Nov
Strong BuyBuyHoldSellStrong Sell
RATING
SEP
OCT
NOV
Strong Buy
0
0
0
Buy
1
1
1
Hold
0
0
0
Sell
0
0
0
Strong Sell
0
0
0
Total
1
1
1
As of Nov, 1 of 1 firms rate GTBP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GTBP EPS & revenue forecast
EPS · NEXT QUARTER
$-2.50
Range $-2.50 – $-2.50 · 1 analysts · -98% YoY
Next period, 1 analysts expect GT Biopharma Inc to earn $-2.50 a share (range $-2.50 – $-2.50), versus $-121.00 a year earlier. Full-year consensus is $-10.75, growing to $-8.00 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering GT Biopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GTBP.
#1
Jonathan Aschoff
Roth MKM · Rank #453
Buy
$3.00-49.6% to target
Overall win rate
28%
+ Follow
GTBP stock forecast FAQ
Who is the most accurate analyst covering GTBP?+
Among analysts who currently cover GTBP, Jonathan Aschoff of Roth MKM has the strongest overall Quantellect track record (Rank #453). Their current call is Buy with a $3.00 target.
What is GT Biopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-2.50 per share (range $-2.50 – $-2.50) across 1 analysts. Full-year EPS is projected at $-10.75, rising to $-8.00 the following year.
How much revenue is GT Biopharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading GTBP lately?+
As of Nov, 1 of 1 firms rate GTBP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GTBP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
